Annexin 1 and melanocortin peptide therapy for protection against ischaemic-reperfusion damage in the heart

TheScientificWorldJournal

Volumn 6, Issue , 2006, Pages 1008-1023

  Gavins, F N E ^a   Leoni, G ^a   Getting, S J ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

Annexin 1; Anti inflammatory; Chemokine; Cytokine; Heart; Ischaemic reperfusion; Macrophage; Melanocortin; Migration; Neutrophil

Indexed keywords

ANNEXIN; ANNEXIN 1; ATENOLOL; CANDESARTAN; DIGOXIN; ENALAPRIL; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELANOCORTIN; MELANOCORTIN RECEPTOR; METFORMIN; METHYLDOPA; NIFEDIPINE; NITRATE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; WARFARIN;

AMINO TERMINAL SEQUENCE; CELL SURVIVAL; DRUG EFFECT; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; REVIEW;

ANIMALS; ANNEXIN A1; HUMANS; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; PRO-OPIOMELANOCORTIN; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 33748955521     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2006.196     Document Type: Review

References (105)

1. Jordan, J.E., Zhao, Z.Q., and Vinten-Johansen, J. (1999) The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43, 860-878.
2. Moens, A.L., Claeys, M.J., Timmermans, J.P., and Vrints, C.J. (2005) Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int. J. Cardiol. 100, 179-190.
3. Ambrosio, G. and Tritto, I. (1999) Reperfusion injury: experimental evidence and clinical implications. Am. Heart J. 138, S69-75.
4. Garlick, P.B., Davies, M.J., Hearse, D.J., and Slater, T.F. (1987) Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ. Res. 61, 757-760.
5. Zweier, J.L. (1988) Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J. Biol. Chem. 263, 1353-1357.
6. Frangogiannis, N.G., Smith, C.W., and Entman, M.L. (2002) The inflammatory response in myocardial infarction. Cardiovasc. Res. 53, 31-47.
7. Carden, D.L. and Granger, D.N. (2000) Pathophysiology of ischaemia-reperfusion injury. J. Pathol. 190, 255-266.
8. Glyn, M.C. and Ward, B.J. (2000) Contraction in cardiac endothelial cells contributes to changes in capillary dimensions following ischaemia and reperfusion. Cardiovasc. Res. 48, 346-356.
9. Romson, J.L., Hook, B.G., Kunkel, S.L., Abrams, G.D., Schork, M.A., and Lucchesi, B.R. (1983) Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67, 1016-1023.
10. Litt, M.R., Jeremy, R.W., Weisman, H.F., Winkelstein, J.A., and Becker, L.C. (1989) Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 80, 1816-1827.
11. Weyrich, A.S., Ma, X.Y., Lefer, D.J., Albertine, K.H., and Lefer, A.M. (1993) In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J. Clin. Invest. 91, 2620-2629.
12. Lefer, D.J., Flynn, D.M., and Buda, A.J. (1996) Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion. Am. J. Physiol. 270, H88-98.
13. Eppihimer, M.J. and Schaub, R.G. (2000) P-Selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler. Thromb. Vasc. Biol. 20, 2483-2488.
14. Ma, X.L., Weyrich, A.S., Lefer, D.J., and Lefer, A.M. (1993) Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 72, 403-412.
15. Jones, S.P., Trocha, S.D., Strange, M.B., Granger, D.N., Kevil, C.G., Bullard, D.C., and Lefer, D.J. (2000) Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 279, H2196-2201.
16. Hartman, J.C., Anderson, D.C., Wiltse, A.L., Lane, C.L., Rosenbloom, C.L., Manning, A.M., Humphrey, W.R., Wall, T.M., and Shebuski, R.J. (1995) Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1. Cardiovasc. Res. 30, 47-54.
17. Lefer, D.J., Shandelya, S.M., Serrano, C.V., Jr., Becker, L.C., Kuppusamy, P., and Zweier, J.L. (1993) Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation 88, 1779-1787.
18. Granger, D.N. and Kubes, P. (1994) The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J. Leukoc. Biol. 55, 662-675.
19. Rusnak, J.M., Kopecky, S.L., Clements, I.P., Gibbons, R.J., Holland, A.E., Peterman, H.S., Martin, J.S., Saoud, J.B., Feldman, R.L., Breisblatt, W.M., Simons, M., Gessler, C.J., Jr., and Yu, A.S. (2001) An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am. J. Cardiol. 88, 482-487.
20. Baran, K.W., Nguyen, M., McKendall, G.R., Lambrew, C.T., Dykstra, G., Palmeri, S.T., Gibbons, R.J., Borzak, S., Sobel, B.E., Gourlay, S.G., Rundle, A.C., Gibson, C.M., and Barron, H.V. (2001) Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 104, 2778-2783.
21. Chapman, M.J. (2005) Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc. Drugs Ther. 19, 135-139.
22. Flower, R.J. (1988) Eleventh Gaddum memorial lecture. Lipocortin and the mechanism of action of the glucocorticoids. Br. J. Pharmacol. 94, 987-1015.
23. Perretti, M., Chiang, N., La, M., Fierro, I.M., Marullo, S., Getting, S.J., Solito, E., and Serhan, C.N. (2002) Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302.
24. Parente, L., Di Rosea, M., Flower, R.J., Ghiara, P., Meli, R., Persico, P., Salmon, J.A., and Wood, J.N. (1984) Relationship between the anti-phospholipase and anti-inflammatory effects of glucocorticoid-induced proteins. Eur. J. Pharmacol. 99, 233-239.
25. Cirino, G., Peers, S.H., Flower, R.J., Browning, J.L., and Pepinsky, R.B. (1989) Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc. Natl. Acad. Sci. U. S. A. 86, 3428-3432.
26. Perretti, M. and Flower, R.J. (1996) Measurement of lipocortin 1 levels in murine peripheral blood leukocytes by flow cytometry: kodulation by glucocorticoids and inflammation. Br. J. Pharmacol. 118, 605-610.
27. Kim, H.W., Choi, E., Yoo, B., Choi, J.R., Park, Y.M., Lee, S.O., Moon, H.B., and Na, D.S. (1996) Lipocortin 1 binding sites on human T-cells: the population of cells with the binding sites is larger in CD8+ T-lymphocytes than in CD4+ T-lymphocytes. Biochem. Mol. Biol. Int. 40, 1167-1173.
28. Morand, E.F., Hutchinson, P., Hargreaves, A., Goulding, N.J., Boyce, N.W., and Holdsworth, S.R. (1995) Detection of intracellular lipocortin 1 in human leukocyte subsets. Clin. Immunol. Immunopathol. 76, 195-202.
29. Perretti, M., Christian, H., Wheller, S.K., Aiello, I., Mugridge, K.G., Morris, J.F., Flower, R.J., and Goulding, N.J. (2000) Annexin I is stored within gelatinase granules of human neutrophil and mobilized on the cell surface upon adhesion but not phagocytosis. Cell. Biol. Int. 24, 163-174.
30. Perretti, M. and Flower, R.J. (1995) Anti-inflammatory lipocortin-derived peptides. Agents Actions Suppl. 46, 131-138.
31. Perretti, M. (1997) Endogenous mediators that inhibit the leukocyte-endothelium interaction. Trends Pharmacol. Sci. 18, 418-425.
32. D'Amico, M., Di Filippo, C., La, M., Solito, E., McLean, P.G., Flower, R.J., Oliani, S.M., and Perretti, M. (2000) Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB. J. 14, 1867-1869.
33. Perretti, M., Ahluwalia, A., Harris, J.G., Goulding, N.J., and Flower, R.J. (1993) Lipocortin-1 fragments inhibit neutrophil accumulation and neutrophil-dependent edema in the mouse. A qualitative comparison with an anti-CD11b monoclonal antibody. J. Immunol. 151, 4306-4314.
34. Gavins, F.N., Yona, S., Kamal, A.M., Flower, R.J., and Perretti, M. (2003) Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood 101, 4140-4147.
35. Lim, L.H., Solito, E., Russo-Marie, F., Flower, R.J., and Perretti, M. (1998) Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Proc. Natl. Acad. Sci. U. S. A. 95, 14535-14539.
36. Miele, L., Cordella-Miele, E., Facchiano, A., and Mukherjee, A.B. (1988) Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature 335, 726-730.
37. van Binsbergen, J., Slotboom, A.J., Aarsman, A.J., and de Haas, G.H. (1989) Synthetic peptide from lipocortin I has no phospholipase A2 inhibitory activity. FEBS Lett. 247, 293-297.
38. Marki, F., Pfeilschifter, J., Rink, H., and Wiesenberg, I. (1990) 'Antiflammins': two nonapeptide fragments of uteroglobin and lipocortin I have no phospholipase A2-inhibitory and anti-inflammatory activity. FEBS Lett. 264, 171-175.
39. Zouki, C., Ouellet, S., and Filep, J.G. (2000) The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells. FASEB J. 14, 572-580.
40. Walther, A., Riehemann, K., and Gerke, V. (2000) A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol. Cell 5, 831-840.
41. Ali, H., Richardson, R.M., Haribabu, B., and Snyderman, R. (1999) Chemoattractant receptor cross-desensitization. J. Biol. Chem. 274, 6027-6030.
42. Durstin, M., Gao, J.L., Tiffany, H.L., McDermott, D., and Murphy, P.M. (1994) Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes. Biochem. Biophys. Res. Commun. 201, 174-179.
43. Shen, W., Proost, P., Li, B., Gong, W., Le, Y., Sargeant, R., Murphy, P.M., Van Damme, J., and Wang, J.M. (2000) Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. Biochem. Biophys. Res. Commun. 272, 276-283.
44. Klein, C., Paul, J.I., Sauve, K., Schmidt, M.M., Arcangeli, L., Ransom, J., Trueheart, J., Manfredi, J.P., Broach, J.R., and Murphy, A.J. (1998) Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 16, 1334-1337.
45. Bao, L., Gerard, N.P., Eddy, R.L., Jr., Shows, T.B., and Gerard, C. (1992) Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. Genomics 13, 437-440.
46. Gavins, F.N., Kamal, A.M., D'Amico, M., Oliani, S.M., and Perretti, M. (2005) Formyl-peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarct. FASEB J. 19, 100-102.
47. Gao, J.L., Chen, H., Filie, J.D., Kozak, C.A., and Murphy, P.M. (1998) Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse. Genomics 51, 270-276.
48. Wang, Z.G. and Ye, R.D. (2002) Characterization of two new members of the formyl peptide receptor gene family from 129S6 mice. Gene 299, 57-63.
49. Takano, T., Fiore, S., Maddox, J.F., Brady, H.R., Petasis, N.A., and Serhan, C.N. (1997) Aspirin-triggered 15-epilipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704.
50. Le, Y., Gong, W., Li, B., Dunlop, N.M., Shen, W., Su, S.B., Ye, R.D., and Wang, J.M. (1999) Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163, 6777-6784.
51. Chiang, N., Takano, T., Arita, M., Watanabe, S., and Serhan, C.N. (2003) A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol. 139, 89-98.
52. La, M., D'Amico, M., Bandiera, S., Di Filippo, C., Oliani, S.M., Gavins, F.N., Flower, R.J., and Perretti, M. (2001) Annexin 1 peptides protect against experimental myocardial ischemia- reperfusion: analysis of their mechanism of action. FASEB J. 15, 2247-2256.
53. Dreier, R., Schmid, K.W., Gerke, V., and Riehemann, K. (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol. 110, 137-148.
54. Oliani, S.M., Paul-Clark, M.J., Christian, H.C., Flower, R.J., and Perretti, M. (2001) Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression. Am. J. Pathol. 158, 603-615.
55. Vergnolle, N., Comera, C., and Bueno, L. (1995) Annexin 1 is overexpressed and specifically secreted during experimentally induced colitis in rats. Eur. J. Biochem. 232, 603-610.
56. Smith, S.F., Tetley, T.D., Guz, A., and Flower, R.J. (1990) Detection of lipocortin 1 in human lung lavage fluid: lipocortin degradation as a possible proteolytic mechanism in the control of inflammatory mediators and inflammation. Environ. Health Perspect. 85, 135-144.
57. Beuckelmann, D.J., Nabauer, M., Kruger, C., and Erdmann, E. (1995) Altered diastolic[Ca2+]i handling in human ventricular myocytes from patients with terminal heart failure. Am. Heart. J. 129, 684-689.
58. Matteo, R.G. and Moravec, C.S. (2000) Immunolocalization of annexins IV, V and VI in the failing and non-failing human heart. Cardiovasc. Res. 45, 961-970.
59. Ritchie, R.H., Sun, X., Bilszta, J.L., Gulluyan, L.M., and Dusting, G.J. (2003) Cardioprotective actions of an N-terminal fragment of annexin-1 in rat myocardium in vitro. Eur. J. Pharmacol. 461, 171-179.
60. Willmott, N.J., Choudhury, Q., and Flower, R.J. (1997) Effects of dexamethasone and phorbol ester on P2 receptor-coupled Ca2+ signalling and lipocortin 1 presentation in U937 cells. Br. J. Pharmacol. 122, 1055-1060.
61. Reilly, A.M., Sun, X., Williams, D.A., and Dusting, G.J. (1999) Dexamethasone inhibits endotoxin-induced changes in calcium and contractility in rat isolated papillary muscle. Cell Calcium 26, 1-8.
62. Lipton, J.M. and Catania, A. (1997) Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol. Today 18, 140-145.
63. Heinig, J.A., Keeley, F.W., Robson, P., Sower, S.A., and Youson, J.H. (1995) The appearance of proopiomelanocortin early in vertebrate evolution: cloning and sequencing of POMC from a Lamprey pituitary cDNA library. Gen. Comp. Endocrinol. 99, 137-144.
64. Wikberg, J.E., Muceniece, R., Mandrika, I., Prusis, P., Lindblom, J., Post, C., and Skottner, A. (2000) New aspects on the melanocortins and their receptors. Pharmacol. Res. 42, 393-420.
65. Castro, M.G. and Morrison, E. (1997) Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit. Rev. Neurobiol. 11(1), 35-57.
66. von Eggelkraut-Gottanka, R. and Beck-Sickinger, A.G. (2004) Biosynthesis of peptide hormones derived from precursor sequences. Curr. Med. Chem. 11, 2651-2665.
67. Benjannet, S., Rondeau, N., Day, R., Chretien, M., and Seidah, N.G. (1991) PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc. Natl. Acad. Sci. U. S. A. 88, 3564-3568.
68. Catania, A., Gatti, S., Colombo, G., and Lipton, J.M. (2004) Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev. 56, 1-29.
69. Star, R.A., Rajora, N., Huang, J., Stock, R.C., Catania, A., and Lipton, J.M. (1995) Evidence of autocrine modulation of macrophage nitric oxide synthase by a-melanocyte-stimulating hormone. Proc. Natl. Acad. Sci. U. S. A. 92, 8016-8020.
70. Taherzadeh, S., Sharma, S., Chhajlani, V., Gantz, I., Rajora, N., Demitri, M.T., Kelly, I., Zhao, H., Ichiyama, T., Catania, A., and Lipton, J.M. (1999) α-MSH and its receptors in regulation of tumour necrosis factor-a production by human monocyte/macrophages. Am. J. Physiol. 276, R1289-R1294.
71. Bhardwaj, R., Becher, E., Mahnke, K., Hartmeyer, M., Schwarz, T., Scholzen, T., and Luger, T.A. (1997) Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J. Immunol. 158, 3378-3384.
72. Catania, A., Rajora, N., Capsooni, F., Minonzio, F., Star, R.A., and Lipton, J.M. (1996) The neuropeptide α-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 17(4), 675-679.
73. Hartmeyer, M., Scholzen, T., Becher, E., Bhardwaj, R.S., Schwarz, T., and Luger, T.A. (1997) Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J. Immunol. 159, 1930-1937.
74. Bohm, M., Schulte, U., Kalden, H., and Luger, T.A. (1999) Alpha-melanocyte-stimulating hormone modulates activation of NF-kappa B and AP-1 and secretion of interleukin-8 in human dermal fibroblasts. Ann. N Y Acad. Sci. 885, 277-286.
75. Adachi, S., Nakano, T., Vliagoftis, H., and Metcalfe, D.D. (1999) Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J. Immunol. 163, 3363-3368.
76. Neumann Andersen, G., Nagaeva, O., Mandrika, I., Petrovska, R., Muceniece, R., Mincheva-Nilsson, L., and Wikberg, J.E. (2001) MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions. Clin. Exp. Immunol. 126, 441-446.
77. Xia, Y., Wikberg, J.E., and Chhajlani, V. (1995) Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 6, 2193-2196.
78. Penhoat, A., Jaillard, C., and Saez, J.M. (1989) Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells. Proc. Natl. Acad. Sci. U. S. A. 86, 4978-4981.
79. Boston, B.A. and Cone, R.D. (1996) Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology 137(5), 2043-2050.
80. Chhajlani, V. (1996) Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem. Mol. Biol. Int. 38, 73-80.
81. Gantz, I., Konda, Y., Tashiro, T., Shimoto, Y., Miwa, H., Munzert, G., Watson, S.J., DelValle, J., and Yamada, T. (1993) Molecular cloning of a novel melanocortin receptor. J. Biol. Chem. 268(11), 8246-8250.
82. Butler, A.A., Kesterson, R.A., Khong, K., Cullen, M.J., Pelleymounter, M.A., Dekoning, J., Baetscher, M., and Cone, R.D. (2000) A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141, 3518-3521.
83. Getting, S.J., Gibbs, L., Clark, A.J.L., Flower, R.J., and Perretti, M. (1999) POMC gene derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release and inhibit neutrophil migration in acute experimental inflammation. J. Immunol. 162, 7446-7453.
84. Getting, S.J., Allcock, G.H., Flower, R., and Perretti, M. (2001) Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J. Leukoc. Biol. 69, 98-104.
85. Getting, S.J., Christian, H.C., Lam, C.W., Gavins, F.N., Flower, R.J., Schioth, H.B., and Perretti, M. (2003) Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J. Immunol. 170, 3323-3330.
86. Getting, S.J., Christian, H.C., Flower, R.J., and Perretti, M. (2002) Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 46, 2765-2775.
87. Lam, C.W., Getting, S.J., and Perretti, M. (2005) In vitro and in vivo induction of heme oxygenase 1 in mouse macrophages following melanocortin receptor activation. J. Immunol. 174, 2297-2304.
88. Guarini, S., Schioth, H.B., Mioni, C., Cainazzo, M., Ferrazza, G., Giuliani, D., Wikberg, J.E., Bertolini, A., and Bazzani, C. (2002) MC(3) receptors are involved in the protective effect of melanocortins in myocardial ischemia/reperfusion-induced arrhythmias. Naunyn Schmiedebergs Arch. Pharmacol. 366, 177-182.
89. Getting, S.J., Di Filippo, C., Christian, H.C., Lam, C.W., Rossi, F., D'Amico, M., and Perretti, M. (2004) MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct. J. Leukoc. Biol. 76, 845-853.
90. Mountjoy, K.G., Mrtrud, M.T., Low, M.J., Simerly, R.B., and Cone, R.D. (1994) Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 8(10), 1298-1308.
91. Martin, W.J. and MacIntyre, D.E. (2004) Melanocortin receptors and erectile function. Eur. Urol. 45, 706-713.
92. Starowicz, K. and Przewlocka, B. (2003) The role of melanocortins and their receptors in inflammatory processes, nerve regeneration and nociception. Life Sci. 73, 823-847.
93. Buggy, J.J. (1998) Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochem J. 331(Pt 1), 211-216.
94. Taylor, A. and Namba, K. (2001) In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol. Cell Biol. 79, 358-367.
95. Getting, S. (2002) Melanocortin peptides and their receptors: new targets for anti- inflammatory therapy. Trends Pharmacol. Sci. 23, 447.
96. Bazzani, C., Guarini, S., Botticelli, A.R., Zaffe, D., Tomasi, A., Bini, A., Cainazzo, M.M., Ferrazza, G., Mioni, C., and Bertolini, A. (2001) Protective effect of melanocortin peptides in rat myocardial ischemia. J. Pharmacol. Exp. Ther. 297, 1082-1087.
97. Szardenings, M., Muceniece, R., Mutule, I., Mutulis, F., and Wikberg, J.E. (2000) New highly specific agonistic peptides for human melanocortin MC(1) receptor. Peptides 21, 239-243.
98. Kask, A., Rago, L., Mutulis, F., Pahkla, R., Wikberg, J.E., and Schioth, H.B. (1998) Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats. Biochem. Biophys. Res. Commun. 245, 90-93.
99. Grieco, P., Balse, P.M., Weinberg, D., MacNeil, T., and Hruby, V.J. (2000) D-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human MC3 receptor selectivity. J. Med. Chem. 43, 4998-5002.
100. Mioni, C., Giuliani, D., Cainazzo, M.M., Leone, S., Iannone, C., Bazzani, C., Grieco, P., Novellino, E., Tomasi, A., Bertolini, A., and Guarini, S. (2003) Further evidence that melanocortins prevent myocardial reperfusion injury by activating melanocortin MC3 receptors. Eur. J. Pharmacol. 477, 227-234.
101. Robbins, L.S., Nadeau, J.H., Johnson, K.R., Kelly, M.A., Roselli-Rehfuss, L., Baack, E., Mountjoy, K.G., and Cone, R.D. (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72, 827-834.
102. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2, 787-795.
103. Granger, D.N. (1999) Ischemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 6, 167-178.
104. Dewald, O., Frangogiannis, N.G., Zoerlein, M., Duerr, G.D., Klemm, C., Knuefermann, P., Taffet, G., Michael, L.H., Crapo, J.D., Welz, A., and Entman, M.L. (2003) Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 100, 2700-2705.
105. La, M., Tailor, A., D'Amico, M., Flower, R.J., and Perretti, M. (2001) Analysis of the protection afforded by annexin 1 in ischaemia-reperfusion injury: focus on neutrophil recruitment. Eur. J. Pharmacol. 429, 263-278.